Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XSPRAY.ST
- Price
- 32.90
- Stock movement up
- +3.15 (10.59%)
- Company name
- XSpray Pharma AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.22B
- Ent value
- 1.23B
- Price/Sales
- 1148.36
- Price/Book
- 2.09
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 32.68%
- 1 year return
- -19.36%
- 3 year return
- -18.01%
- 5 year return
- -10.35%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
XSPRAY.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1148.36 |
| Price to Book | 2.09 |
| EV to Sales | 1155.26 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.14M |
| EPS (TTM) | -7.64 |
| FCF per share (TTM) | -6.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.06M |
| Gross profit (TTM) | -4.09M |
| Operating income (TTM) | -260.31M |
| Net income (TTM) | -258.05M |
| EPS (TTM) | -7.64 |
| EPS (1y forward) | -2.24 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -384.02% |
| Operating margin (TTM) | -24465.51% |
| Profit margin (TTM) | -24253.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 74.76M |
| Net receivables | 0.00 |
| Total current assets | 101.50M |
| Goodwill | 0.00 |
| Intangible assets | 458.67M |
| Property, plant and equipment | 0.00 |
| Total assets | 667.70M |
| Accounts payable | 19.23M |
| Short/Current long term debt | 33.61M |
| Total current liabilities | 53.54M |
| Total liabilities | 82.10M |
| Shareholder's equity | 585.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -193.39M |
| Capital expenditures (TTM) | 39.87M |
| Free cash flow (TTM) | -233.26M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -44.07% |
| Return on Assets | -38.65% |
| Return on Invested Capital | -43.69% |
| Cash Return on Invested Capital | -39.49% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 30.00 |
| Daily high | 33.00 |
| Daily low | 28.85 |
| Daily Volume | 27K |
| All-time high | 258.00 |
| 1y analyst estimate | 76.00 |
| Beta | 0.84 |
| EPS (TTM) | -7.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 May 2025 |
Downside potential
Loading...
Downside potential data
| XSPRAY.ST | S&P500 | |
| Current price drop from All-time high | -87.25% | -12.04% |
| Highest price drop | -89.90% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -54.32% | -11.07% |
| Avg time to new high | 49 days | 12 days |
| Max time to new high | 1184 days | 1805 days |
COMPANY DETAILS
Marketcap
1.22B
Marketcap category
Small-cap
Description
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company's product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
Employees
24
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
STOCKHOLM, September 19, 2024--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today ann...
September 19, 2024
STOCKHOLM, September 06, 2024--A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap™ technology improves the bioavailability...
September 6, 2024
STOCKHOLM, July 09, 2024--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its proprietar...
July 9, 2024
STOCKHOLM, May 23, 2024--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of marke...
May 23, 2024